시장보고서
상품코드
1808925

세계의 바이럴 벡터 위탁개발생산기관 시장 : 유형별, 워크플로우 단계별, 규모별, 용도별, 국가별, 지역별 - 산업 분석, 규모, 점유율, 예측(2025-2032년)

Viral Vector Contract Development Manufacturing Organizations Market, By Vector Type, By Workflow Stage, By Scale, By Application, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 378 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

바이럴 벡터 위탁개발생산기관 시장 규모는 2024년에 11억 2,300만 달러로 평가되었고, 2025년부터 2032년까지 연평균 복합 성장률(CAGR) 18.5%로 확대될 전망입니다.

바이럴 벡터 위탁개발생산기관(CDMO) 시장은 유전자 치료, 백신 및 세포 기반 치료에 사용되는 바이럴 벡터 제조의 아웃소싱 서비스에 중점을 둡니다. 2024년 중반까지 전 세계적으로 30개 이상의 유전자 치료가 승인되었으며, AAV, 렌티바이러스 및 아데노바이럴 벡터의 시험 파이프라인이 확대됨으로써 전문 제조에 대한 수요가 추진되고 있습니다. 제약회사와 바이오테크놀러지 기업으로부터의 투자 증가는 CDMO의 규모 확대를 뒷받침하고 있으며, 서모피셔 사이언티픽은 2023년에 6억 5,000만 달러를 투입해 세포 및 유전자 치료 네트워크를 확대하고 있습니다. 그러나 높은 생산 비용, 복잡한 바이오프로세스, 바이러스 안전성 및 일관성에 대한 규제 당국의 모니터링은 CDMO의 진전을 억제할 수 있습니다. 그럼에도 불구하고 전략적 파트너십, 플랫폼 표준화 및 국내 벡터 생산이 부족한 지역 수요 증가를 통해 비즈니스 기회가 탄생하고 있습니다.

바이럴 벡터 위탁개발생산기관 시장 - 시장 역학

유전자 치료 파이프라인의 확대와 생명공학 투자가 바이럴 벡터 위탁개발생산기관 시장 성장을 가속화

유전자 치료 파이프라인의 급속한 확대와 생명공학 투자 증가는 바이럴 벡터 위탁개발생산기관 시장의 성장을 가속화하고 있습니다. 미국 FDA와 Alliance for Regenerative Medicine에 따르면 2024년 현재 세계에서 2,000건 이상의 유전자 치료 임상시험이 실시되고 있습니다. 이러한 급증으로 대형 제약 기업은 확장성과 컴플라이언스의 요구를 충족시키기 위해 벡터 생산을 전문 CDMO에 위탁하게 되었습니다. 2023년 미국 바이오메디컬 첨단 연구개발국(BARDA)은 해외 공급에 대한 의존도를 줄이기 위해 국내에서 바이럴 벡터 제조를 확대할 자금을 수여했습니다. 캐터런트사나 서모피셔 사이언티픽사 등의 기업은 바이럴 벡터의 인프라를 강화하기 위해 수억 달러를 투자해, 종양학이나 희귀질환 치료에 있어서의 AAV나 렌티바이럴 벡터 수요 증가에 대응하고 있습니다. 이러한 추세는 북미와 유럽에서 장기적인 CDMO 파트너십과 전략적 능력 확대에 대한 명확한 경향을 뒷받침합니다.

바이럴 벡터 위탁개발생산기관 시장 - 세분화 분석 :

세계의 바이럴 벡터 위탁개발생산기관 시장은 벡터 유형, 워크플로우 단계, 규모, 용도 및 지역에 따라 구분됩니다.

시장은 벡터 유형에 따라 아데노바이러스, 렌티바이러스, 아데노 관련 바이러스, 레트로바이러스, 단순 헤르페스 바이러스, 하이브리드/키메라 벡터의 6가지 범주로 나뉩니다. 아데노 관련 바이러스(AAV)는 유전자 도입에 있어서의 안전성과 효율의 높이가 증명되고 있기 때문에 톱이며, 안정적인 유전자 도입이 가능한 렌티바이러스가 이어지고 있습니다. 레트로 바이러스, 단순 헤르페스 바이러스, 하이브리드 벡터는 틈새 치료에 사용됩니다.

워크플로우 단계별로는 업스트림 공정(세포 배양(HEK293, Sf9), 형질감염/감염 프로토콜), 다운스트림 공정(여과 및 크로마토그래피, 초원심분리, 최종 제품화)의 두 가지 범주로 나뉩니다. 업스트림 공정이 우선되어 HEK293 세포 배양과 최적화된 형질감염 프로토콜이 확장 가능한 벡터 생산에 널리 사용되고 있습니다. 벡터의 안정성과 임상 등급의 품질을 보장하기 위해서는 초 원심 분리와 최종 제제화가 필수적입니다.

바이럴 벡터 위탁개발생산기관 시장 - 지리적 통찰

북미는 견고한 바이오파마 생태계, 정부의 자금 지원, 고급 인프라를 지원하며 바이럴 벡터 위탁개발생산기관 시장에서 주도적인 지위를 차지합니다. 2023년에 서모피셔 사이언티픽사는 메릴랜드주 시설을 확장하여 AAV 벡터의 생산을 강화하고 미국 FDA는 유전자 치료 승인을 계속 가속화하고 있습니다. 유럽도 중요한 거점이며 독일, 영국, 네덜란드에서는 수탁 제조 수요가 높아지고 있습니다. 2024년 6월, 캐터런트사는 옥스포드 바이오메디카사와 제휴해, 유럽의 고객용으로 바이럴 벡터의 제조 규모를 확대했습니다. 한편 아시아태평양은 중국, 일본, 한국을 필두로 급속히 대두하고 있으며, 세포 및 유전자 치료에 대한 정부 지원 증가로 현지 CDMO는 능력을 증강하고 있습니다. 2024년 일본의 AGC 바이오로직스는 지바에 바이럴 벡터 생산 라인을 설립하기 위해 현지 유전자 치료 기업과의 전략적 제휴를 발표했습니다.

바이럴 벡터 위탁개발생산기관 시장 - 경쟁 구도 :

바이럴 벡터 위탁개발생산기관 시장 특징은 주요 기업의 전략적 움직임과 생산 능력의 확대입니다. 써모피셔 사이언티픽은 2019년에 Brammer Bio를, 2021년 1월에 Novasep의 Henogen 부문을 약 7억 2,500만 유로(약 8억 7,500만 달러)로 인수해, 유럽의 바이럴 벡터 사업을 대폭 강화하는 것과 동시에, 렉싱턴, 케임브리지 플레인, 지난 10년간 FDA가 승인한 신약의 절반 이상을 지원해, 50개 이상의 시설에서 연간 약 700억 도즈를 생산해 온 Catalent는 2024년 12월에 노보 홀딩스에 165억 달러로 인수되어, 의약품, 유전자 치료, 주사 전달의 각 분야에 있어서 수탁 제조 시장의 판도를 재편하고 있습니다. Catalent가 Sarepta Therapeutics나 다수의 COVID-19 백신 제조업체와 제휴하고 있는 것처럼, 지역적인 제휴는 경쟁을 더욱 격화시킵니다. 이러한 M&A와 제휴 전략을 합치면 규모, 세계적인 커버리지, 치료 특화에 의해 차별화가 강화하는 것을 보여줍니다.

목차

제1장 바이럴 벡터 위탁개발생산기관 시장 개요

  • 조사 범위
  • 시장 추정 연도

제2장 주요 요약

  • 시장 분석
  • 경쟁 인사이트

제3장 바이럴 벡터 위탁개발생산기관의 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장 전망 동향

제4장 바이럴 벡터 위탁개발생산기관의 업계 조사

  • PEST 분석
  • Porter's Five Forces 분석
  • 성장 전망 맵핑
  • 규제 틀 분석

제5장 바이럴 벡터 위탁개발생산기관 시장 : 높아지는 지정학적 긴장의 영향

  • COVID-19 팬데믹의 영향
  • 러시아-우크라이나 전쟁의 영향
  • 중동 분쟁의 영향

제6장 바이럴 벡터 위탁개발생산기관 시장 상황

  • 바이럴 벡터 위탁개발생산기관 시장 점유율 분석, 2024년
  • 주요 제조업체별 분석 데이터
    • 기존 기업의 분석
    • 신규 기업의 분석

제7장 바이럴 벡터 위탁개발생산기관 시장 - 벡터 유형별

  • 개요
    • 벡터 유형별 부문 점유율 분석
    • 아데노바이러스
    • 렌티바이러스
    • 아데노 관련 바이러스
    • 레트로바이러스
    • 단순 헤르페스 바이러스
    • 하이브리드/키메라 벡터

제8장 바이럴 벡터 위탁개발생산기관 시장 - 워크플로우 단계별

  • 개요
    • 워크플로우 단계별 부문 점유율 분석
    • 업스트림 처리
      • 세포 배양(HEK293, Sf9)
      • 트랜스펙션/감염 프로토콜
    • 하류 처리
      • 여과와 크로마토그래피
      • 초원심 분리
      • 최종 제품의 배합

제9장 바이럴 벡터 위탁개발생산기관 시장 - 규모별

  • 개요
    • 규모별 부문 점유율 분석
    • 전임상(연구개발 배치)
    • 임상(Phase I-III)
    • 상용(시장 공급 가능)

제10장 바이럴 벡터 위탁개발생산기관 시장 - 용도별

  • 개요
    • 용도별 부문 점유율 분석
    • 유전자 치료
    • 암 면역요법
    • 감염증 백신
    • 희소질환의 치료

제11장 바이럴 벡터 위탁개발생산기관 시장 - 지역별

  • 소개
  • 북미
    • 개요
    • 북미의 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽의 주요 제조업체
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인
    • 네덜란드
    • 스웨덴
    • 러시아
    • 폴란드
    • 기타
  • 아시아태평양
    • 개요
    • 아시아태평양의 주요 제조업체
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주
    • 인도네시아
    • 태국
    • 필리핀
    • 기타
  • 라틴아메리카
    • 개요
    • 라틴아메리카의 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 중동 및 아프리카의 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 튀르키예
    • 알제리
    • 이집트
    • 기타

제12장 주요 벤더 분석 - 바이럴 벡터 위탁개발생산기관 업계

  • 경쟁 대시보드
    • 경쟁 벤치마킹
    • 경쟁 포지셔닝
  • 기업 프로파일
    • AGC Biologics
    • Aldevron
    • Batavia Biosciences
    • BioReliance(Merck KGaA)
    • Catalent
    • Charles River Laboratories
    • Cobra Biologics(Charles River)
    • FUJIFILM Diosynth Biotechnologies
    • Genezen
    • iBET
    • Kaneka Eurogentec
    • Lonza
    • Novasep
    • Oxford Biomedica
    • REGENXBIO(CDMO Services arm)
    • Thermo Fisher Scientific(Patheon)
    • Vigene Biosciences(Charles River)
    • VIVEbiotech
    • WuXi Advanced Therapies
    • Yposkesi
    • 기타

제13장 애널리스트의 전방위적 전망

SHW 25.09.26

Viral Vector Contract Development Manufacturing Organizations Market size was valued at US$ 1,123 Million in 2024, expanding at a CAGR of 18.5% from 2025 to 2032.

The Viral Vector Contract Development and Manufacturing Organizations (CDMO) Market focuses on outsourcing services for the production of viral vectors used in gene therapies, vaccines, and cell-based treatments. Over 30 gene therapy approvals globally by mid-2024 and an expanding pipeline of AAV, lentiviral, and adenoviral vector trials are fueling demand for specialized manufacturing. Rising investments from pharma and biotech firms are pushing CDMOs to scale up, with Thermo Fisher Scientific investing $650 million in 2023 to expand its cell and gene therapy network. However, high production costs, complex bioprocessing, and regulatory scrutiny over viral safety and consistency may restrain progress. Nonetheless, opportunities are emerging through strategic partnerships, platform standardization, and rising demand from regions lacking domestic vector production.

Viral Vector Contract Development Manufacturing Organizations Market- Market Dynamics

Expanding Gene Therapy Pipeline and Biotech Investments Accelerate Growth of Viral Vector CDMO Market

The rapid expansion of gene therapy pipelines and increased biotech investments are accelerating the growth of the viral vector CDMO market. As of 2024, over 2,000 gene therapy clinical trials are active globally, according to the U.S. FDA and Alliance for Regenerative Medicine. This surge has prompted major pharmaceutical players to outsource vector production to specialized CDMOs to meet scalability and compliance needs. In 2023, the U.S. Biomedical Advanced Research and Development Authority (BARDA) awarded funding to expand domestic viral vector manufacturing to reduce reliance on overseas supply. Companies like Catalent and Thermo Fisher Scientific have invested hundreds of millions to enhance viral vector infrastructure, addressing the rising demand for AAV and lentiviral vectors in oncology and rare disease therapies. These developments underscore a clear trend toward long-term CDMO partnerships and strategic capacity expansion across North America and Europe.

Viral Vector Contract Development Manufacturing Organizations Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 18.5% over the forecast period (2025-2032)

Based on Vector Type segmentation, Adeno-associated virus (AAV) was predicted to show maximum market share in the year 2024

Based on Workflow Stage segmentation, Upstream processing was the leading Workflow Stage in 2024

Based on Scale segmentation, the Clinical scale was the leading Scale in 2024

On the basis of region, North America was the leading revenue generator in 2024

Viral Vector Contract Development Manufacturing Organizations Market- Segmentation Analysis:

The Global Viral Vector Contract Development Manufacturing Organizations Market is segmented on the basis of Vector Type, Workflow Stage, Scale, Application, and Region.

The market is divided into six categories based on Vector Type: Adenovirus, Lentivirus, Adeno-associated Virus, Retrovirus, Herpes Simplex Virus, and Hybrid/Chimeric Vectors. Adeno-associated virus (AAV) leads due to its proven safety and efficiency in gene delivery, followed by lentivirus for stable gene integration. Adenovirus ranks third for vaccine development, while retrovirus, herpes simplex virus, and hybrid vectors are used in niche therapies.

The market is divided into two categories based on Workflow Stage: Upstream Processing (Cell culture (HEK293, Sf9), Transfection/infection protocols), and Downstream Processing (Filtration & Chromatography, Ultracentrifugation, Final Product Formulation). Upstream processing holds priority, with HEK293 cell culture and optimized transfection protocols widely used for scalable vector production. Downstream processing follows, where filtration and chromatography dominate purification, while ultracentrifugation and final formulation are essential for ensuring vector stability and clinical-grade quality.

Viral Vector Contract Development Manufacturing Organizations Market- Geographical Insights

North America holds a leading position in the viral vector CDMO market, supported by a robust biopharma ecosystem, government funding, and advanced infrastructure. In 2023, Thermo Fisher Scientific expanded its Maryland facility to enhance AAV vector production, while the U.S. FDA continued to accelerate approvals for gene therapies. Europe is also a key hub, with growing demand for contract manufacturing in Germany, the UK, and the Netherlands. In June 2024, Catalent collaborated with Oxford Biomedica to scale up viral vector manufacturing for European clients. Meanwhile, the Asia-Pacific region is emerging rapidly, led by China, Japan, and South Korea, where increasing government support for cell and gene therapy is prompting local CDMOs to boost capabilities. In 2024, Japan's AGC Biologics announced a strategic partnership with a local gene therapy company to establish viral vector production lines in Chiba, signaling regional capacity strengthening.

Viral Vector Contract Development Manufacturing Organizations Market- Competitive Landscape:

The viral vector CDMO market features strategic moves and capacity expansion among top players. Thermo Fisher Scientific leads the charge, acquiring Brammer Bio in 2019 and Novasep's Henogen division in January 2021 for approximatel €725 million (~$875 million), significantly enhancing its European viral vector footprint and complementing U.S. operations in Lexington, Cambridge, Plainville, and Alachua. Catalent-supporting over half of FDA-approved new drugs in the past decade and producing roughly 70 billion doses annually across 50+ facilities-was acquired by Novo Holdings for $16.5 billion in December 2024, reshaping contract manufacturing dynamics across drug, gene therapy, and injection delivery segments. Regional collaborations further enrich competition, such as Catalent's partnerships with Sarepta Therapeutics and multiple COVID-19 vaccine manufacturers. Together, these M&A and alliance strategies demonstrate intensifying differentiation through scale, global coverage, and therapeutic specialization.

Recent Developments:

In June 2025, ProBio opened a 128,000 sq ft GMP facility in Hopewell, New Jersey, to produce plasmid DNA and viral vectors. The site will begin AAV manufacturing by Q3 2025 and LVV services by Q1 2026.

In May 2024, Charles River Laboratories launched a viral vector tech transfer program, offering two frameworks-Fast Track for seamless transfers and Modular for customizable applications-to accelerate process handoffs to its Maryland Center of Excellence in as little as nine months.

In September 2024, Rentschler Biopharma launched a comprehensive lentiviral vector (LVV) manufacturing toolbox at its advanced therapies facility in Stevenage, UK, complementing its existing AAV services. This includes process development, cGMP manufacturing, and a royalty-free HEK293 cell line to accelerate ATMP production.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL VIRAL VECTOR CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AGC Biologics
  • Aldevron
  • Batavia Biosciences
  • BioReliance (Merck KGaA)
  • Catalent
  • Charles River Laboratories
  • Cobra Biologics (Charles River)
  • FUJIFILM Diosynth Biotechnologies
  • Genezen
  • iBET
  • Kaneka Eurogentec
  • Lonza
  • Novasep
  • Oxford Biomedica
  • REGENXBIO (CDMO Services arm)
  • Thermo Fisher Scientific (Patheon)
  • Vigene Biosciences (Charles River)
  • VIVEbiotech
  • WuXi Advanced Therapies
  • Yposkesi
  • Others

GLOBAL VIRAL VECTOR CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS MARKET, BY VECTOR TYPE- MARKET ANALYSIS, 2019 - 2032

  • Adenovirus
  • Lentivirus
  • Adeno-associated Virus
  • Retrovirus
  • Herpes Simplex Virus
  • Hybrid/Chimeric Vectors

GLOBAL VIRAL VECTOR CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS MARKET, BY WORKFLOW STAGE- MARKET ANALYSIS, 2019 - 2032

  • Upstream Processing
  • Cell culture (HEK293, Sf9)
  • Transfection/infection protocols
  • Downstream Processing
  • Filtration & Chromatography
  • Ultracentrifugation
  • Final Product Formulation

GLOBAL VIRAL VECTOR CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS MARKET, BY SCALE- MARKET ANALYSIS, 2019 - 2032

  • Preclinical (R&D batches)
  • Clinical (Phase I-III)
  • Commercial (Market-ready supply)

GLOBAL VIRAL VECTOR CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Gene Therapy
  • Cancer Immunotherapy
  • Infectious Disease Vaccines
  • Rare Disease Treatment

GLOBAL VIRAL VECTOR CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Viral Vector Contract Development Manufacturing Organizations Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Viral Vector Contract Development Manufacturing Organizations Market Snippet by Vector Type
    • 2.1.2. Viral Vector Contract Development Manufacturing Organizations Market Snippet by Workflow Stage
    • 2.1.3. Viral Vector Contract Development Manufacturing Organizations Market Snippet by Scale
    • 2.1.4. Viral Vector Contract Development Manufacturing Organizations Market Snippet by Application
    • 2.1.5. Viral Vector Contract Development Manufacturing Organizations Market Snippet by Country
    • 2.1.6. Viral Vector Contract Development Manufacturing Organizations Market Snippet by Region
  • 2.2. Competitive Insights

3. Viral Vector Contract Development Manufacturing Organizations Key Market Trends

  • 3.1. Viral Vector Contract Development Manufacturing Organizations Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Viral Vector Contract Development Manufacturing Organizations Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Viral Vector Contract Development Manufacturing Organizations Market Opportunities
  • 3.4. Viral Vector Contract Development Manufacturing Organizations Market Future Trends

4. Viral Vector Contract Development Manufacturing Organizations Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Viral Vector Contract Development Manufacturing Organizations Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Viral Vector Contract Development Manufacturing Organizations Market Landscape

  • 6.1. Viral Vector Contract Development Manufacturing Organizations Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Viral Vector Contract Development Manufacturing Organizations Market - By Vector Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Vector Type, 2024 & 2032 (%)
    • 7.1.2. Adenovirus
    • 7.1.3. Lentivirus
    • 7.1.4. Adeno-associated Virus
    • 7.1.5. Retrovirus
    • 7.1.6. Herpes Simplex Virus
    • 7.1.7. Hybrid/Chimeric Vectors

8. Viral Vector Contract Development Manufacturing Organizations Market - By Workflow Stage

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Workflow Stage, 2024 & 2032 (%)
    • 8.1.2. Upstream Processing
      • 8.1.2.1. Cell culture (HEK293, Sf9)
      • 8.1.2.2. Transfection/infection protocols
    • 8.1.3. Downstream Processing
      • 8.1.3.1. Filtration & Chromatography
      • 8.1.3.2. Ultracentrifugation
      • 8.1.3.3. Final Product Formulation

9. Viral Vector Contract Development Manufacturing Organizations Market - By Scale

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Scale, 2024 & 2032 (%)
    • 9.1.2. Preclinical (R&D batches)
    • 9.1.3. Clinical (Phase I-III)
    • 9.1.4. Commercial (Market-ready supply)

10. Viral Vector Contract Development Manufacturing Organizations Market - By Application

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 10.1.2. Gene Therapy
    • 10.1.3. Cancer Immunotherapy
    • 10.1.4. Infectious Disease Vaccines
    • 10.1.5. Rare Disease Treatment

11. Viral Vector Contract Development Manufacturing Organizations Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Viral Vector Contract Development Manufacturing Organizations Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Viral Vector Contract Development Manufacturing Organizations Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Viral Vector Contract Development Manufacturing Organizations Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Viral Vector Contract Development Manufacturing Organizations Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Viral Vector Contract Development Manufacturing Organizations Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Workflow Stage, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Scale, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Viral Vector Contract Development Manufacturing Organizations Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. AGC Biologics
    • 12.2.2. Aldevron
    • 12.2.3. Batavia Biosciences
    • 12.2.4. BioReliance (Merck KGaA)
    • 12.2.5. Catalent
    • 12.2.6. Charles River Laboratories
    • 12.2.7. Cobra Biologics (Charles River)
    • 12.2.8. FUJIFILM Diosynth Biotechnologies
    • 12.2.9. Genezen
    • 12.2.10. iBET
    • 12.2.11. Kaneka Eurogentec
    • 12.2.12. Lonza
    • 12.2.13. Novasep
    • 12.2.14. Oxford Biomedica
    • 12.2.15. REGENXBIO (CDMO Services arm)
    • 12.2.16. Thermo Fisher Scientific (Patheon)
    • 12.2.17. Vigene Biosciences (Charles River)
    • 12.2.18. VIVEbiotech
    • 12.2.19. WuXi Advanced Therapies
    • 12.2.20. Yposkesi
    • 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제